5-Amino-1MQ: an elegant mechanism with no human trials

5-Amino-1MQ is one of the more mechanistically elegant compounds in the longevity-and-fat-loss space, and one of the least proven in humans. It targets a real, interesting enzyme with a coherent metabolic rationale — and then the evidence stops at the edge of the animal lab. This monograph is mostly about being honest about that gap.

What it is and how it’s supposed to work

First, like tesofensine, 5-Amino-1MQ is not a peptide — it’s a small molecule (5-amino-1-methylquinolinium). It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and is overexpressed in fat and muscle tissue in metabolic disease.^[3] The logic is a flux argument: NNMT consumes nicotinamide (a building block of NAD+) and a methyl group to make a waste product, 1-methylnicotinamide. Block NNMT, and you spare both the NAD+ salvage pool and the cell’s methyl-donor (SAM) supply — which, in fat cells, suppresses the machinery of fat storage (lipogenesis).^[1] It is conceptually adjacent to the NAD+ precursor story, approached from the other direction: instead of adding NAD+ building blocks, you stop wasting them.

The mouse evidence

The foundational study treated diet-induced obese mice with a potent NNMT inhibitor and reported that it reduced body weight and white adipose mass, decreased fat-cell size, and lowered cholesterol — without changing how much the mice ate, and without observable adverse effects.^[1]That “no change in food intake” detail is the interesting part: the weight loss appeared to come from changing fat-cell metabolism, not from appetite suppression. A 2024 follow-up in obese mice found 5-Amino-1MQ dose-dependently limited body-weight and fat gains, improved glucose tolerance and insulin sensitivity, and reduced fatty liver over 28 days.^[2] The compound has also shown effects on aged-muscle regeneration in elderly mice.^[4]

Who is behind the research

For an evidence-first read, the provenance matters. Much of the 5-Amino-1MQ obesity and muscle work comes from one academic lineage and its commercial spin-out (the developers are affiliated with the company commercializing the lead NNMT inhibitor).^[1][2] That does not make the science wrong — the findings are published in peer-reviewed journals — but it means independent replication is thin, and the enthusiasm in the marketing outruns the breadth of the evidence. As of now, that company has no registered human clinical trials of the compound.

The honest bottom line

5-Amino-1MQ has a clean, plausible mechanism and a real preclinical signal: in mice, inhibiting NNMT reduces fat without cutting food intake, by sparing the NAD+ and methyl pool.^[1] But it has never been tested in a human clinical trial, so its weight-loss, safety, and dosing claims for people are inferences, not findings. It is sold as a research chemical, not an approved medicine. Treat it as a genuinely interesting preclinical idea worth watching — and treat anyone selling it as a proven fat-loss product as far ahead of the data. For metabolic compounds with actual human outcome trials, see our weight-loss evidence roundup.